English

GT Biopharma, Inc.

EDGAR

GTBP Registration statement (S-1) · filed 2026-10-09

167 filing records in this dataset, filed from 1995-05-12 to 2026-10-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2021 Q3 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-3.93 million USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -11901000 USD Source
Operating Cash Flow: -7972000 USD Source

Cash and cash equivalents: 4.96 million USD 2026-06-30 Source
Exact value

4960000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 44.7 million shares 2026-06-30 Source
Exact value

44668969 shares

Reported share-count change

1,264.77% · 41.4 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

3272995 shares · 2025-06-30· Source
44668969 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

-14.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -8893000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -5216000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -12900000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -8893000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2500000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -6700000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -2500000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-09.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2020-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 5 of 11 periods available· newest 2019-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2023-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 15.24 million

Prior period

−USD 13.16 million

2024-01-01 – 2024-12-31
Current period

−USD 28.4 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-28400000 − -13162000 = -15238000 USD

-13162000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-28400000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · GT Biopharma, Inc. · 2025-12-31 GT Biopharma, Inc. (edgar:109657) Year-over-year change in Net income: -15238000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -28400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#929562 Filing: 000149315226008443 Input fundies:NetIncome: -13162000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#887832 Filing: 000149315226008443
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 4,000

Prior period

−USD 12.9 million

2024-01-01 – 2024-12-31
Current period

−USD 12.9 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-12900000 − -12904000 = 4000 USD

-12904000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-12900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · GT Biopharma, Inc. · 2025-12-31 GT Biopharma, Inc. (edgar:109657) Year-over-year change in Operating cash flow: 4000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -12900000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#929984 Filing: 000149315226008443 Input fundies:OperatingCashFlow: -12904000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#899734 Filing: 000149315226008443
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 0
Operating costs Derived USD 6.76 million
Operating income −USD 6.76 million
Tax, interest and other Derived USD 21.53 million
Net income −USD 28.3 million

Cash

Operating cash flow −USD 7.26 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	9374000 Derived	-9374000	-19142000 Derived	9768000	-1930000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -9374000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 9768000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -1930000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 0 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	135570000 Derived	-135570000	8602000 Derived	-144172000	-5434000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -135570000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -144172000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -5430000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 4000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	250069000 Derived	-250069000	9117000 Derived	-259186000	-10713000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -250069000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -259186000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -10677000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 36000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	-16056000 Derived	16056000	54703000 Derived	-38647000	-3659000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 16056000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -38647000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -3659000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 0 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	6764000 Derived	-6764000	21532000 Derived	-28296000	Unavailable	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -6764000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -28296000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -7262000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	27000	Revenue: 27000 Open source
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source
20182018-12-31	Revenue	0	Revenue: 0 Open source
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 27000 Open source
20162016-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 27000 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -33,063% 2015

Net margin -79,485.2% 2015

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-33,063%	Operating Income: -8927000 Open source Revenue: 27000 Open source
20162016-12-31	Operating margin	Not reported	Operating Income: -9374000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -135570000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -250069000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: 16056000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -6764000 Open source Revenue: 0 Open source
20152015-12-31	Net margin	-79,485.2%	Net Income: -21461000 Open source Revenue: 27000 Open source
20162016-12-31	Net margin	Not reported	Net Income: 9768000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -144172000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -259186000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -38647000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -28296000 Open source Revenue: 0 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 27000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1930000 Open source Capital Expenditure: 0 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -5430000 Open source Capital Expenditure: 4000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -10677000 Open source Capital Expenditure: 36000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -3659000 Open source Capital Expenditure: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -7262000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -7.3M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	-1930000	Operating Cash Flow: -1930000 Open source
20172017-12-31	Operating cash flow	-5430000	Operating Cash Flow: -5430000 Open source
20182018-12-31	Operating cash flow	-10677000	Operating Cash Flow: -10677000 Open source
20192019-12-31	Operating cash flow	-3659000	Operating Cash Flow: -3659000 Open source
20202020-12-31	Operating cash flow	-7262000	Operating Cash Flow: -7262000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -3.7M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	-1930000	Operating Cash Flow: -1930000 Open source Capital Expenditure: 0 Open source
20172017-12-31	Free cash flow	-5434000	Operating Cash Flow: -5430000 Open source Capital Expenditure: 4000 Open source
20182018-12-31	Free cash flow	-10713000	Operating Cash Flow: -10677000 Open source Capital Expenditure: 36000 Open source
20192019-12-31	Free cash flow	-3659000	Operating Cash Flow: -3659000 Open source Capital Expenditure: 0 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -7262000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

4,976.3% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	93,746.3%	Total Liabilities: 50623000 Open source Total Assets: 54000 Open source
20162016-12-31	Liabilities / assets	75,796%	Total Liabilities: 18949000 Open source Total Assets: 25000 Open source
20172017-12-31	Liabilities / assets	1.1%	Total Liabilities: 2679000 Open source Total Assets: 254368000 Open source
20182018-12-31	Liabilities / assets	55.2%	Total Liabilities: 14029000 Open source Total Assets: 25399000 Open source
20192019-12-31	Liabilities / assets	4,976.3%	Total Liabilities: 19706000 Open source Total Assets: 396000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 5661000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.16× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	0×	Current Assets: 49000 Open source Current Liabilities: 49909000 Open source
20162016-12-31	Current assets / current liabilities	0×	Current Assets: 21000 Open source Current Liabilities: 18949000 Open source
20172017-12-31	Current assets / current liabilities	0.22×	Current Assets: 576000 Open source Current Liabilities: 2679000 Open source
20182018-12-31	Current assets / current liabilities	0.01×	Current Assets: 90000 Open source Current Liabilities: 14029000 Open source
20192019-12-31	Current assets / current liabilities	0.01×	Current Assets: 274000 Open source Current Liabilities: 19706000 Open source
20202020-12-31	Current assets / current liabilities	0.16×	Current Assets: 5661000 Open source Current Liabilities: 35094000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	USD 9.77 million Exact value Exact value: 9768000 USD 2016-01-01 – 2016-12-31: 9768000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2016-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: 9768000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: 9768000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495418002054/gtbp-20171231.xml#56001 Filing: 000165495418002054 The citation records this snapshot. The page link may show a newer release later.	−USD 1.93 million Exact value Exact value: -1930000 USD 2016-01-01 – 2016-12-31: -1930000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2016-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -1930000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1930000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495418002054/gtbp-20171231.xml#58837 Filing: 000165495418002054 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2016-01-01 – 2016-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GT Biopharma, Inc. · 2016-12-31 GT Biopharma, Inc. (edgar:109657) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495418002054/gtbp-20171231.xml#59203 Filing: 000165495418002054 The citation records this snapshot. The page link may show a newer release later.	−USD 1.93 million Calculation and evidence -1930000 − 0 USD Exact free cash flow: -1930000 USD 2016-01-01 – 2016-12-31: -1930000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GT Biopharma, Inc. · 2016-12-31 GT Biopharma, Inc. (edgar:109657) Free cash flow: -1930000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1930000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495418002054/gtbp-20171231.xml#58837 Filing: 000165495418002054 Input fundies:CapitalExpenditure: 0 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495418002054/gtbp-20171231.xml#59203 Filing: 000165495418002054 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 144.17 million Exact value Exact value: -144172000 USD 2017-01-01 – 2017-12-31: -144172000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2017-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -144172000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -144172000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495419010735/gtbp-20190630.xml#59347 Filing: 000165495419010735 The citation records this snapshot. The page link may show a newer release later.	−USD 5.43 million Exact value Exact value: -5430000 USD 2017-01-01 – 2017-12-31: -5430000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2017-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -5430000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5430000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495419010735/gtbp-20190630.xml#68156 Filing: 000165495419010735 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2017-01-01 – 2017-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GT Biopharma, Inc. · 2017-12-31 GT Biopharma, Inc. (edgar:109657) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495419010735/gtbp-20190630.xml#71142 Filing: 000165495419010735 The citation records this snapshot. The page link may show a newer release later.	−USD 5.43 million Calculation and evidence -5430000 − 4000 USD Exact free cash flow: -5434000 USD 2017-01-01 – 2017-12-31: -5430000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GT Biopharma, Inc. · 2017-12-31 GT Biopharma, Inc. (edgar:109657) Free cash flow: -5434000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5430000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495419010735/gtbp-20190630.xml#68156 Filing: 000165495419010735 Input fundies:CapitalExpenditure: 4000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495419010735/gtbp-20190630.xml#71142 Filing: 000165495419010735 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 259.19 million Exact value Exact value: -259186000 USD 2018-01-01 – 2018-12-31: -259186000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2018-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -259186000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -259186000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495420013481/gtbp-20200930.xml#43692 Filing: 000165495420013481 The citation records this snapshot. The page link may show a newer release later.	−USD 10.68 million Exact value Exact value: -10677000 USD 2018-01-01 – 2018-12-31: -10677000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2018-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -10677000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10677000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495420013481/gtbp-20200930.xml#77263 Filing: 000165495420013481 The citation records this snapshot. The page link may show a newer release later.	USD 36,000 Exact value Exact value: 36000 USD 2018-01-01 – 2018-12-31: 36000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GT Biopharma, Inc. · 2018-12-31 GT Biopharma, Inc. (edgar:109657) Capital Expenditure: 36000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 36000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495420013481/gtbp-20200930.xml#78001 Filing: 000165495420013481 The citation records this snapshot. The page link may show a newer release later.	−USD 10.71 million Calculation and evidence -10677000 − 36000 USD Exact free cash flow: -10713000 USD 2018-01-01 – 2018-12-31: -10677000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 36000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GT Biopharma, Inc. · 2018-12-31 GT Biopharma, Inc. (edgar:109657) Free cash flow: -10713000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10677000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495420013481/gtbp-20200930.xml#77263 Filing: 000165495420013481 Input fundies:CapitalExpenditure: 36000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495420013481/gtbp-20200930.xml#78001 Filing: 000165495420013481 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 38.65 million Exact value Exact value: -38647000 USD 2019-01-01 – 2019-12-31: -38647000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2019-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -38647000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38647000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp-20201231.xml#62651 Filing: 000165495421004295 The citation records this snapshot. The page link may show a newer release later.	−USD 3.66 million Exact value Exact value: -3659000 USD 2019-01-01 – 2019-12-31: -3659000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2019-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -3659000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3659000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp-20201231.xml#71976 Filing: 000165495421004295 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2019-01-01 – 2019-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · GT Biopharma, Inc. · 2019-12-31 GT Biopharma, Inc. (edgar:109657) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495420013481/gtbp-20200930.xml#77822 Filing: 000165495420013481 The citation records this snapshot. The page link may show a newer release later.	−USD 3.66 million Calculation and evidence -3659000 − 0 USD Exact free cash flow: -3659000 USD 2019-01-01 – 2019-12-31: -3659000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · GT Biopharma, Inc. · 2019-12-31 GT Biopharma, Inc. (edgar:109657) Free cash flow: -3659000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3659000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp-20201231.xml#71976 Filing: 000165495421004295 Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000165495420013481/gtbp-20200930.xml#77822 Filing: 000165495420013481 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 28.3 million Exact value Exact value: -28296000 USD 2020-01-01 – 2020-12-31: -28296000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2020-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -28296000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28296000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315222007883/form10-k.htm#965567 Filing: 000149315222007883 The citation records this snapshot. The page link may show a newer release later.	−USD 7.26 million Exact value Exact value: -7262000 USD 2020-01-01 – 2020-12-31: -7262000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2020-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -7262000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7262000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315222007883/form10-k.htm#1396290 Filing: 000149315222007883 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 58.01 million Exact value Exact value: -58013000 USD 2021-01-01 – 2021-12-31: -58013000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2021-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -58013000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58013000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315223009812/form10-k.htm#1089608 Filing: 000149315223009812 The citation records this snapshot. The page link may show a newer release later.	−USD 15.61 million Exact value Exact value: -15606000 USD 2021-01-01 – 2021-12-31: -15606000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2021-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -15606000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15606000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315223009812/form10-k.htm#1104637 Filing: 000149315223009812 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 20.88 million Exact value Exact value: -20884000 USD 2022-01-01 – 2022-12-31: -20884000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2022-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -20884000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20884000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315224011332/form10-k.htm#1144178 Filing: 000149315224011332 The citation records this snapshot. The page link may show a newer release later.	−USD 15.22 million Exact value Exact value: -15217000 USD 2022-01-01 – 2022-12-31: -15217000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2022-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -15217000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15217000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315224011332/form10-k.htm#1158735 Filing: 000149315224011332 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 7.6 million Exact value Exact value: -7597000 USD 2023-01-01 – 2023-12-31: -7597000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2023-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -7597000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7597000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315225007908/form10-k.htm#1012896 Filing: 000149315225007908 The citation records this snapshot. The page link may show a newer release later.	−USD 8.85 million Exact value Exact value: -8852000 USD 2023-01-01 – 2023-12-31: -8852000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2023-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -8852000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8852000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315225007908/form10-k.htm#1037275 Filing: 000149315225007908 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 13.16 million Exact value Exact value: -13162000 USD 2024-01-01 – 2024-12-31: -13162000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2024-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -13162000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13162000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#887832 Filing: 000149315226008443 The citation records this snapshot. The page link may show a newer release later.	−USD 12.9 million Exact value Exact value: -12904000 USD 2024-01-01 – 2024-12-31: -12904000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2024-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -12904000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12904000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#899734 Filing: 000149315226008443 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 28.4 million Exact value Exact value: -28400000 USD 2025-01-01 – 2025-12-31: -28400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · GT Biopharma, Inc. · 2025-12-31 GT Biopharma, Inc. (edgar:109657) Net Income: -28400000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#929562 Filing: 000149315226008443 The citation records this snapshot. The page link may show a newer release later.	−USD 12.9 million Exact value Exact value: -12900000 USD 2025-01-01 – 2025-12-31: -12900000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · GT Biopharma, Inc. · 2025-12-31 GT Biopharma, Inc. (edgar:109657) Operating Cash Flow: -12900000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:14:15Z Snapshot: b8a125c18dac575eda869138712c20f2ee498e1a3f8c46c68bc91d490c1d465b Dimensions: Consolidated View: https://fundies.io/companies/edgar/109657/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12900000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm#929984 Filing: 000149315226008443 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

167 filings · 3,388 latest values · 3,388 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000109657, 109657, GTBP, edgar:109657

Also known as GT BIOPHARMA, INC., GT BIOPHARMA, INC, GT BIOPHARMA, INC., GT Biopharma, Inc., OXIS INTERNATIONAL INC

GT Biopharma, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Operating cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation